share_log

Mangoceuticals | AW: Withdrawal of amendment to a registration statement filed under the Securities Act

Mangoceuticals | AW: Withdrawal of amendment to a registration statement filed under the Securities Act

Mangoceuticals | AW：撤销修改注册声明
美股SEC公告 ·  08/30 17:28

Moomoo AI 已提取核心信息

Mangoceuticals, Inc., a pharmaceutical company based in Dallas, Texas, has formally requested the withdrawal of its Post-Effective Amendment No. 1 to the Registration Statement on Form S-1, initially filed with the U.S. Securities and Exchange Commission (SEC). The request, dated August 30, 2024, and submitted via EDGAR, was made under Rule 477 of the Securities Act of 1933. The company has decided not to proceed with the deregistration of certain shares of common stock that were previously registered under the statement. This withdrawal request is specific to the Post-Effective Amendment and does not affect any other filings with the SEC under the same file number. Jacob D. Cohen, Chairman and Chief Executive Officer of Mangoceuticals, signed the withdrawal request.
Mangoceuticals, Inc., a pharmaceutical company based in Dallas, Texas, has formally requested the withdrawal of its Post-Effective Amendment No. 1 to the Registration Statement on Form S-1, initially filed with the U.S. Securities and Exchange Commission (SEC). The request, dated August 30, 2024, and submitted via EDGAR, was made under Rule 477 of the Securities Act of 1933. The company has decided not to proceed with the deregistration of certain shares of common stock that were previously registered under the statement. This withdrawal request is specific to the Post-Effective Amendment and does not affect any other filings with the SEC under the same file number. Jacob D. Cohen, Chairman and Chief Executive Officer of Mangoceuticals, signed the withdrawal request.
位于德克萨斯州达拉斯的制药公司Mangoceuticals, Inc.，已正式请求撤回其在美国证券交易委员会（SEC）初次提交的文件S-1注册声明的Post-Effective Amendment No. 1。该请求于2024年8月30日提交，并通过EDGAR进行了提交，符合《1933年证券法》规则477的规定。公司决定不进行先前在申报文件中注册的普通股的注销。此次撤回请求仅限于Post-Effective Amendment，不会影响在同一文件编号下提交给SEC的其他文件。Mangoceuticals的主席兼首席执行官Jacob D. Cohen签署了撤回请求。
位于德克萨斯州达拉斯的制药公司Mangoceuticals, Inc.，已正式请求撤回其在美国证券交易委员会（SEC）初次提交的文件S-1注册声明的Post-Effective Amendment No. 1。该请求于2024年8月30日提交，并通过EDGAR进行了提交，符合《1933年证券法》规则477的规定。公司决定不进行先前在申报文件中注册的普通股的注销。此次撤回请求仅限于Post-Effective Amendment，不会影响在同一文件编号下提交给SEC的其他文件。Mangoceuticals的主席兼首席执行官Jacob D. Cohen签署了撤回请求。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间